ArticleClinical drug investigation2026
Proton Pump Inhibitor Co-prescription, Dabigatran Use, and Ischaemic Stroke or Transient Ischaemic Attack in Atrial Fibrillation: A Population-Based Case-Control Study.
Article in Clinical drug investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
BACKGROUND AND
objectivesProton pump inhibitors (PPIs) reduce gastric acidity and lower dabigatran plasma concentrations, raising concern about a clinically relevant drug-drug interaction. We examined whether PPI co-prescription modified the association between dabigatran use and atrial fibrillation (AF)-associated ischaemic stroke (IS) or transient ischaemic attack (TIA).
methodsWe conducted a population-based case-control study of adults with AF in Auckland, New Zealand. Cases were patients with adjudicated IS/TIA between September 2020 and August 2021 identified from the fifth Auckland Regional Community Stroke Study, which uses multiple overlapping ascertainment sources and independent clinical adjudication. Controls were patients with AF from the same source population who remained free of IS/TIA during the surveillance period, sampled from the Ministry of Health National Minimum Dataset. Individual-level demographics, comorbidities and medication exposures were obtained from electronic clinical records and dispensing data. Multivariable logistic regression included dabigatran use, PPI use and their interaction term, with adjustment for pre-specified clinical covariates.
resultsThe analytic sample comprised 300 IS/TIA cases and 1,608 controls. Dabigatran use was associated with lower odds of IS/TIA (adjusted odds ratio [aOR] 0.36 [95%CI 0.24-0.53]). PPI use was associated with higher odds of IS/TIA (aOR 1.55 [95%CI 1.08-2.24]), but this association is likely subject to residual confounding and should not be interpreted as causal. The dabigatran × PPI interaction was not statistically significant (aOR 0.98 [95%CI 0.57-1.69]; p = 0.94).
conclusionWe found no evidence of a large dabigatran-specific interaction with PPI co-prescription. These findings do not support a major clinically important attenuation of dabigatran's association with lower odds of AF-associated IS/TIA, although modest effect modification cannot be excluded. Generalisability to lower-risk primary-care AF populations and healthcare systems with different patient characteristics may be limited.
Identifiers
42829417What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.